UNSPSC 51102866: Neomycin/prednisolone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102866 Neomycin/prednisolone is a Commodity code that nominally designates a specific pharmaceutical product, but recent state and local solicitations tagged under it actually address a much broader procurement landscape spanning naloxone, medical and first aid supplies, generic multi-source pharmaceuticals, and over-the-counter products. The code does not align cleanly with the work being solicited; issuing bodies appear to be using it as a catch-all for pharmaceutical and medical supply acquisitions rather than purchasing neomycin/prednisolone specifically. State and local buyers under this code include county public health departments, city fire departments, state health and human services agencies, and multi-state cooperative purchasing alliances seeking to source pharmaceutical products and emergency medical supplies for community health, emergency response, and employee health benefit programs.

Recent activity spans Florida, Texas, Minnesota, and participating cooperative-purchasing states. The Seminole County, Florida IFB 60459723LAS (due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to county health facilities. The City of Tampa's ITB 26P00145 (due March 13, 2026) solicited 169 line items of medical and first aid supplies—including respiratory equipment, cardiac electrodes, endotracheal tubes, and consumables—for the Tampa Fire Department Rescue Division on a one-year award with two one-year renewal options, with an estimated contract value of $700,000 and a sheltered market set-aside for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs serving self-insured employee group health plans and state agencies outside traditional pharmacy benefit manager arrangements.